Activated recombinant factor VII (rFVIIa)

Best Practice and Research: Clinical Anaesthesiology

Volumn 24, Issue 1, 2010, Pages 95-106

  Grottke, Oliver ^a   Henzler, Dietrich ^b   Rossaint, Rolf ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

blood; coagulation trauma; haemorrhage; perioperative; recombinant activated factor VIIa

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7 INHIBITOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING INHIBITOR; EPTACOG ALFA; FIBRINOGEN; FRESH FROZEN PLASMA; PLACEBO; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL SURGERY; ACIDOSIS; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CASE STUDY; CLINICAL TRIAL; CRYOPRECIPITATE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEMATOCRIT; HEMOPHILIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; LIVER FAILURE; LIVER RESECTION; LIVER TRANSPLANTATION; OFF LABEL DRUG USE; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; POSTPARTUM HEMORRHAGE; PREGNANCY; PRIORITY JOURNAL; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE; REVIEW; SKIN TRANSPLANTATION; SYSTEMATIC ERROR; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; TRAUMATOLOGY; UROLOGIC SURGERY; VASCULAR SURGERY;

ANIMALS; BLOOD COAGULATION DISORDERS; FACTOR VIIA; HEMOSTATICS; HUMANS; MONITORING, INTRAOPERATIVE; PERIOPERATIVE CARE; RECOMBINANT PROTEINS; VITAMIN K;

EID: 77649106855     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2009.09.005     Document Type: Review

References (109)

1. Hoffmann M.M.D. A cell-based model of hemostasis. Thrombosis and Haemostasis 85 (2001) 958-965
2. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. Journal of Biotechnology 124 (2006) 747-757
3. Hoffman M., and Monroe III D.M. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Seminars in Hematology 38 (2001) 6-9
4. Monroe D.M., Hoffman M., Oliver J.A., et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. British Journal of Haematology 99 (1997) 542-547
5. Lisman T., Adelmeijer J., Cauwenberghs S., et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. Journal of Thrombosis and Haemostasis 3 (2005) 742-745
6. Wolberg A.S., Allen G.A., Monroe D.M., et al. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. British Journal of Haematology 131 (2005) 645-655
7. Hedner U., and Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annual Review of Medicine 59 (2008) 29-41
8. Hedner U., and Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. The Journal of Clinical Investigation 71 (1983) 1836-1841
9. Hedner U., Glazer S., Pingel K., et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 2 (1988) 1193
10. Hedner U. Treatment of patients with factor VII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thrombosis and Haemostasis 82 (1999) 531-539
11. Parr M.J., Bouillon B., Brohi K., et al. Traumatic coagulopathy: where are the good experimental models?. The Journal of Trauma 65 (2008) 766-771
12. Friederich P.W., Henny C.P., Messelink E.J., et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361 (2003) 201-205
13. Raobaikady R., Redman J., Ball J.A., et al. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. British Journal Of Anaesthesia 94 (2005) 586-591
14. Von Heymann C., Jonas S., Spies C., et al. Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Critical Care 12 (2008) R14
15. Ranucci M., Isgrò G., Soro G., et al. Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Archives of Surgery 143 (2008) 296-304
16. da Silva Viana J. Recombinant factor VIIa in major abdominal surgery and liver transplantation. Transplantation Proceedings 38 (2006) 818-819
17. Hendriks H.G., Meijer K., de Wolf J.T., et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 71 (2001) 402-405
18. Niemann C.U., Behrends M., Quan D., et al. Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores. Transfusion Medicine 16 (2006) 93-100
19. Planinsic R.M., van der Meer J., Testa G., et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transplantation 11 (2005) 895-900
20. Lodge J.P., Jonas S., Jones R.M., et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transplantation 11 (2005) 973-979
21. Gala B., Quintela J., Aguirrezabalaga J., et al. Benefits of recombinant activated factor VII in complicated liver transplantation. Transplantation Proceedings 37 (2005) 3919-3921
22. Lodge J.P., Jonas S., Oussoultzoglou E., et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 102 (2005) 269-275
23. Shao Y.F., Yang J.M., Chau G.Y., et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. American Journal of Surgery 191 (2006) 245-249
24. Warren O., Mandal K., Hadjianastassiou V., et al. Recombinant activated factor VII in cardiac surgery: a systematic review. The Annals of Thoracic Surgery 83 (2007) 707-714
25. Tanos M.D.J. Is recombinant activated factor VII useful for intractable bleeding after cardiac surgery?. Interactive Cardiovascular and Thoracic Surgery 5 (2006) 493-498
26. McCall P., Story D.A., and Karapillai D. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Canadian Journal of Anaesthesia 53 (2006) 926-933
27. Walsham J., Fraser J.F., Mullany D., et al. The use of recombinant activated factor VII for refractory bleeding post complex cardiothoracic surgery. Anaesthesia and Intensive Care 34 (2006) 13-20
28. Romagnoli S., Bevilacqua S., Gelsomino S., et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesthesia and Analgesia 102 (2006) 1320-1326
29. Gelsomino S., Lorusso R., Romagnoli S., et al. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis. European Journal of Cardio-Thoracic Surgery 33 (2008) 64-71
30. Tritapepe L., De Santis V., Vitale D., et al. Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis. Critical Care Medicine 35 (2007) 1685-1690
31. Hardy J.F., Bélisle S., and Van der Linden P. Efficacy and safety of activated recombinant factor VII in cardiac surgical patients. Current Opinion in Anaesthesiology 22 (2009) 95-99
32. Diprose P., Herbertson M.J., O'Shaughnessy D., et al. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex noncoronary cardiac surgery: randomized double-blind placebocontrolled pilot study. British Journal of Anaesthesia 95 (2005) 596-602
33. Ekert H., Brizard C., Eyers R., et al. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagulation & Fibrinolysis 17 (2006) 389-395
34. Available at:. http://clinicaltrials.gov/ct2/show/NCT00154427 [accessed June 2009]
35. Sauaia A., Moore F.A., Moore E.E., et al. Epidemiology of trauma deaths: a reassessment. Journal of Trauma 38 (1995) 185-193
36. Kauvar D.S., and Wade C.E. The epidemiology and modern management of traumatic hemorrhage: US and international perspectives. Critical Care 9 (2005) 1-9
37. Kenet G., Walden R., Eldad A., et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354 (1999) 1879
38. Rizoli S.B., Nascimento Jr. B., Osman F., et al. Recombinant activated coagulation factor VII and bleeding trauma patients. Journal of Trauma 61 (2006) 1419-1425
39. Dutton R.P., McCunn M., Hyder M., et al. Factor VIIa for correction of traumatic coagulopathy. Journal of Trauma 57 (2004) 709-718
40. Harrison T.D., Laskosky J., Jazaeri O., et al. "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. Journal of Trauma 59 (2005) 150-154
41. Geeraedts Jr. L.M., Kamphuisen P.W., Kaasjager H.A., et al. The role of recombinant factor VIIa in the treatment of life-threatening haemorrhage in blunt trauma. Injury 36 (2005) 495-500
42. Gowers C.J., and Parr M.J. Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy. Anaesthesia and Intensive Care 33 (2005) 196-200
43. Udy A., Vaghela M., Lawton G., et al. The use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma. Anaesthesia 60 (2005) 613-616
44. Martinowitz U.M.M. The Israeli Multidisciplinary rFVIIa Task Force Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. Journal of Thrombosis and Haemostasis 3 (2005) 640-648
45. Spinella P.C., Perkins J.G., McLaughlin D.F., et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. Journal of Trauma 64 (2008) 286-293
46. Boffard K.D., Riou B., Warren B., et al. NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. Journal of Trauma 5 (2005) 8-15
47. Kluger Y., Riou B., Rossaint R., et al. Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial. Critical Care 11 (2007) R85
48. Available at:. http://clinicaltrials.gov/ct2/show/NCT00184548 [accessed June 2009]
49. Vincent J.L., Rossaint R., Riou B., et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding-a European perspective. Critical Care 10 (2006) R120
50. Ronsmans C., and Graham W.J. Lancet maternal survival series steering group. Maternal mortality: who, when, where, and why. Lancet 368 (2006) 1189-1200
51. Henrich W., Surbek D., Kainer F., et al. Diagnosis and treatment of peripartum bleeding. Journal Of Perinatal Medicine 36 (2008) 467-478
52. Ahonen J., Jokela R., and Korttila K. An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage. Acta Anaesthesiologica Scandinavica 51 (2007) 929-936
53. Franchini M., Franchi M., Bergamini V., et al. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Seminars in Thrombosis and Hemostasis 34 (2008) 104-112
54. Sachs B., Delacy D., Green J., et al. Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. Spine 32 (2007) 2285-2293
55. Johansson P.I., Eriksen K., Nielsen S.L., et al. Recombinant FVIIa decreases perioperative blood transfusion requirement in burn patients undergoing excision and skin grafting-results of a single centre pilot study. Burns 33 (2007) 435-440
56. Kucher N., Castellanos L.R., Quiroz R., et al. Time trends in warfarin-associated hemorrhage. American Journal of Cardiology 94 (2004) 403-406
57. Levy J.H., Tanaka K.A., and Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 109 (2008) 918-926
58. Leissinger C.A., Blatt P.M., Hoots W.K., et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. American Journal of Hematology 83 (2008) 137-143
59. Mallarkey G., Brighton T., Thomson A., et al. An evaluation of eptacog alfa in nonhaemophiliac conditions. Drugs 68 (2008) 1665-1689
60. Girard P., Nony P., Erhardtsen E., et al. Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thrombosis and Haemostasis 80 (1998) 109-113
61. Dager W.E., King J.H., Regalia R.C., et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 26 (2006) 1091-1098
62. Levi M. Emergency reversal of antithrombotic treatment. Internal and Emergency Medicine 4 (2009) 137-145
63. Levi M., Bijsterveld N.R., and Keller T.T. Recombinant factor VIIa as an antidote for anticoagulant treatment. Seminars in Hematology 41 (2004) 65-69
64. Baglin T.P., Keeling D.M., and Watson H.G. British committee for standards in haematology. Guidelines on oral anticoagulation (warfarin). -2005 update. British Journal of Haematology 132 (2006) 277-285
65. Santagostino E., Mancuso M.E., Rocino A., et al. A prospective randomized trial of high and standard dosages of re-combinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. Journal of Thrombosis and Haemostasis 4 (2006) 367-371
66. Konkle B., Friedrich U., and Abrams Z. Secondary prophylactic treatment with rFVIIA in patients with haemophilia A or B and inhibitors with high requirements for on-demand treatment. Haemophilia 12 (2006) 363
67. Heuer L., and Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA Class I alloantibodies and thrombocytopenia associated with platelets dysfunction refractory to transfusion of cross matched platelets. Blood Coagulation Fibrinolysis 16 (2005) 287-290
68. Lindley C.M., Sawyer W.T., Macik B.G., et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clinical Pharmacology and Therapeutics 55 (1994) 638-648
69. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thrombosis and Haemostasis 100 (2008) 557-562
70. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Seminars in Thrombosis and Hemostasis 26 (2000) 385-391
71. Hedner U., and Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clinical Advances in Hematology & Oncology 1 (2003) 112-119
72. Stanworth S.J., Birchall J., Doree C.J., et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systermic Reviews 2 (2007) CD005011
73. Hsia C.C., Chin-Yee I.H., and McAlister V.C. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Annals of Surgery 248 (2008) 61-68
74. Meng Z.H., Wolberg A.S., Monroe III D.M., et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. Journal of Trauma 55 (2003) 886-891
75. Negrier C., Dargaud Y., and Bordet J.C. Basic aspects of bypassing agents. Haemophilia 12 (2006) 48-52
76. Spahn D.R., and Rossaint R. Coagulopathy and blood component transfusion in trauma. British Journal of Anaesthesia 95 (2005) 130-139
77. Roberts H.R., Monroe D.M., and White G.C. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 104 (2004) 3858-3864
78. Eikelboom J.W., Bird R., Blythe D., et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagulation & Fibrinolysis 14 (2003) 713-717
79. Moisescu E., Ardelean L., Simion I., et al. Recombinant factor VIIa treatment of bleeding associated with acute renal failure. Blood Coagulation & Fibrinolysis 11 (2000) 575-577
80. Carr Jr. M.E., and Martin E. Recombinant factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential. Expert Review of Cardiovascular Theraphy 2 (2004) 661-674
81. Telgt D.S., Macik B.G., McCord D.M., et al. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thrombosis Research 56 (1989) 603-609
82. Rao L.V., and Rapaport S.I. Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood 75 (1990) 1069-1073
83. Shima M. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis. Seminars in Hematology 41 (2004) 125-131
84. Sørensen B., Johansen P., Christiansen K., et al. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. Journal of Thrombosis and Haemostasis 1 (2003) 551-558
85. Dehmel H., Werwitzke S., Trummer A., et al. Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia. Haemophilia 14 (2008) 736-742
86. Young G., Ebbesen L.S., Viuff D., et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagulation & Fibrinolysis 19 (2008) 276-282
87. Gabriel D.A., Carr M., and Roberts H.R. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Seminars in Hematology 41 (2004) 20-24
88. Dargaud Y., Lambert T., and Trossaert M. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia 14 (2008) 20-27
89. Young G., Yonekawa K.E., Nakagawa P.A., et al. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagulation & Fibrinolysis 18 (2007) 547-553
90. James K.M., Melikian C.N., Chowdary P., et al. Thromboelastography-guided recombinant factor VIIa administration in a patient with refractory autoimmune idiopathic thrombocytopenia. Anesthesia and Analgesia 107 (2008) 402-405
91. Bartal C., and Yitzhak A. The role of thromboelastometry and recombinant factor VIIa in trauma. Current Opinion in Anaesthesiology 22 (2009) 281-288
92. Levrat A., Gros A., Rugeri L., et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. British Journal of Anaesthesia 100 (2008) 792-797
93. Cid A.R., Lorenzo J.I., Haya S., et al. A comparison of FVII: C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia 7 (2001) 39-41
94. Hemker H.C., Giesen P., AlDieri R., et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiology of Haemostasis and Thrombosis 32 (2002) 249-253
95. Pusateri A.E., and Park M.S. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Critical Care 9 (2005) 15-24
96. Levi M., Peters M., and Büller H.R. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Critical Care Medicine 33 (2005) 883-890
97. Bui J.D., Despotis G.D., Trulock E.P., et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. The Journal of Thoracic and Cardiovascular Surgery 124 (2002) 852-854
98. Bijsterveld N.R., Moons A.H., Boekholdt S.M., et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106 (2002) 2550-2554
99. Bijsterveld N.R., Vink R., van Aken B.E., et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. British Journal of Haematology 124 (2004) 653-658
100. Fridberg M.J., Hedner U., Roberts H.R., et al. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagulation & Fibrinolysis 16 (2005) 259-266
101. Wolzt M., Levi M., Sarich T.C., et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thrombosis and Haemostasis 91 (2004) 1090-1096
102. Roberts H.R. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagulation & Fibrinolysis 9 (1998) 115-118
103. Roberts H.R. Recombinant factor VIIa (Novoseven) and the safety of treatment. Seminars in Hematology 38 (2001) 48-50
104. O'Connell K.A., Wood J.J., Wise R.P., et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. The Journal of the American Medical Association 295 (2006) 293-298
105. Available at:. www.emea.europa.eu//humandocs/PDFs/EPAR/Novoseven/072995en8b [accessed June 2009]
106. Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiologica 73 (2007) 401-415
107. Grottke O., Henzler D., and Rossaint R. Use of blood and blood products in trauma. Best Practice & Research. Clinical Anaesthesiology 21 (2007) 257-270
108. Brohi K., Cohen M.J., and Davenport R.A. Acute coagulopathy of trauma: mechanism, identification and effect. Current Opinion in Critical Care 13 (2007) 680-685
109. Spahn D.R., Cerny V., Coats T.J., et al. Task Force for Advanced Bleeding Care in Trauma. Management of bleeding following major trauma: a European guideline. Critical Care 11 (2007) R17